多种生物制剂及靶向合成改善病情抗风湿药转换的原因与治疗难治性类风湿关节炎的特征
在2001至2017年多医院类风湿关节炎电子健康记录队列中,识别6040例使用至少一种生物制剂或靶向合成改善病情抗风湿药的患者,其中404例符合EULAR「难治性」标准,15%为难治性类风湿关节炎。停药最常见原因为应答不足(43.3%)、疗效丧失(25.8%)和非过敏性不良事件(13.7%)。难治性患者开始用药时更年轻、女性及曾吸烟者比例更高,但无类风湿关节炎临床因素可区分难治性患者与用药起始者。
要点
- 停药最常见原因为应答不足(43.3%)、疗效丧失(25.8%)和非过敏性不良事件(13.7%)。
- 符合EULAR「难治性」标准的患者中15%为难治性类风湿关节炎。
- 难治性患者开始用药时更年轻、女性及曾吸烟者比例更高,但无类风湿关节炎临床因素可区分。
核心结论
- 生物制剂及靶向合成改善病情抗风湿药转换最常见原因为应答不足、疗效丧失和非过敏性不良事件(如感染、白细胞减少、银屑病)。
- 类风湿关节炎临床因素不足以区分生物制剂及靶向合成改善病情抗风湿药应答者与无应答者。
研究设计与样本
- 多医院类风湿关节炎电子健康记录队列研究,纳入2001至2017年间处方至少一种生物制剂或靶向合成改善病情抗风湿药的患者。
- 依据EULAR「难治性」类风湿关节炎定义,识别停用至少两种不同作用机制生物制剂或靶向合成改善病情抗风湿药的患者,并进行人工病历审查确定停药原因。
- 治疗难治性类风湿关节炎定义为尽管使用两种不同作用机制生物制剂或靶向合成改善病情抗风湿药,仍未达到低疾病活动度(压痛或肿胀关节数少于3个且每日泼尼松等效剂量低于7.5 mg)。
- 比较治疗难治性类风湿关节炎患者与未达EULAR「难治性」标准的生物制剂或靶向合成改善病情抗风湿药起始者之间的人口学、生活方式和临床因素。
主要发现
- 共识别6040例使用至少一种生物制剂或靶向合成改善病情抗风湿药的患者,其中404例符合EULAR「难治性」标准。
- 停药最常见原因为应答不足(43.3%)、疗效丧失(25.8%)和非过敏性不良事件(13.7%)。
- 符合EULAR「难治性」标准的患者中15%为治疗难治性类风湿关节炎。
- 治疗难治性类风湿关节炎患者开始生物制剂或靶向合成改善病情抗风湿药时更年轻(平均47.2岁 vs 55.2岁,p<0.001),女性比例更高(91.8% vs 76.1%,p=0.006),曾吸烟者比例更高(68.9% vs 49.9%,p=0.005)。
- 无类风湿关节炎临床因素可区分治疗难治性类风湿关节炎患者与生物制剂或靶向合成改善病情抗风湿药起始者。
关键数值与推荐
- EULAR「难治性」类风湿关节炎定义:停用至少两种不同作用机制生物制剂或靶向合成改善病情抗风湿药。
- 治疗难治性类风湿关节炎定义:尽管使用两种不同作用机制生物制剂或靶向合成改善病情抗风湿药,仍未达到低疾病活动度(压痛或肿胀关节数少于3个且每日泼尼松等效剂量低于7.5 mg)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was to identify and categorize reasons for b/tsDMARD switching and investigate characteristics associated with treatment refractory RA. METHODS: In a multi-hospital RA electronic health record (EHR) cohort, we identified RA patients prescribed ≥1 b/tsDMARD between 2001 and 2017. Consistent with the EULAR "difficult to treat" (D2T) RA definition, we further identified patients who discontinued ≥2 b/tsDMARDs with different mechanisms of action. We performed manual chart review to determine reasons for medication discontinuation. We defined "treatment refractory" RA as not achieving low disease activity (<3 tender or swollen joints on <7.5 mg of daily prednisone equivalent) despite treatment with two different b/tsDMARD mechanisms of action. We compared demographic, lifestyle, and clinical factors between treatment refractory RA and b/tsDMARD initiators not meeting D2T criteria. RESULTS: We identified 6040 RA patients prescribed ≥1 b/tsDMARD including 404 meeting D2T criteria. The most common reasons for medication discontinuation were inadequate response (43.3 %), loss of efficacy (25.8 %), and non-allergic adverse events (13.7 %). Of patients with D2T RA, 15 % had treatment refractory RA. Treatment refractory RA patients were younger at b/tsDMARD initiation (mean 47.2 vs. 55.2 years, p < 0.001), more commonly female (91.8% vs. 76.1 %, p = 0.006), and ever smokers (68.9% vs. 49.9 %, p = 0.005). No RA clinical factors differentiated treatment refractory RA patients from b/tsDMARD initiators. CONCLUSIONS: In a large EHR-based RA cohort, the most common reasons for b/tsDMARD switching were inadequate response, loss of efficacy, and nonallergic adverse events (e.g. infections, leukopenia, psoriasis). Clinical RA factors were insufficient for differentiating b/tsDMARD responders from nonresponders.
引用
- McDermott GC, DiIorio M, Kawano Y, et al. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. Semin Arthritis Rheum. 2024. PMID: 38457949. doi:10.1016/j.semarthrit.2024.152421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。